Ketamine Alternative Shows Promise

Researchers show that lanicemine is an effective antidepressant without the adverse effects of the related hallucinogenic drug.

Written byAbby Olena, PhD
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, STEVEN DEPOLOKetamine can reduce depressive symptoms, but it induces side effects that make its street drug counterpart, “Special K,” popular at parties: hallucinations, altered perception, and dissociative behavior. But now researchers have shown that a ketamine alternative, lanicemine, can reduce depression without the adverse effects, according to a study published in Molecular Psychiatry this week (October 15).

Researchers from Yale University, the French pharmaceutical company Forenap, and AstraZeneca conducted a double-blind, placebo-controlled study to test the effectiveness of lanicemine in 152 people with treatment-resistant major depressive disorder (MDD). They found that study participants who received lanicemine injections three times a week for three weeks had a greater decrease in depressive symptoms than patients who received the placebo. The patients who received lanicemine also reported no serious adverse effects.

“This is the largest study to date evaluating the antidepressant effects of an NMDA receptor antagonist,” first author Gerard Sanacora, a professor of psychiatry at Yale University, told Everyday Health. Lanicemine and ketamine block NMDA receptors, but it is still not well understood why this seems to reduce depression.

Ketamine has been shown to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • abby olena

    As a freelancer for The Scientist, Abby reports on new developments in life science for the website. She has a PhD from Vanderbilt University and got her start in science journalism as the Chicago Tribune’s AAAS Mass Media Fellow in 2013. Following a stint as an intern for The Scientist, Abby was a postdoc in science communication at Duke University, where she developed and taught courses to help scientists share their research. In addition to her work as a science journalist, she leads science writing and communication workshops and co-produces a conversational podcast. She is based in Alabama.  

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies